Initial Statement of Beneficial Ownership (3)
June 16 2017 - 9:06AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Cavanaugh Sarah
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/15/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
Celldex Therapeutics, Inc. [CLDX]
|
(Last)
(First)
(Middle)
C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
SVP of Corp. Affairs & Admin. /
|
(Street)
HAMPTON, NJ 08827
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock, par value $0.001 per share
|
4760
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Employee Stock Option (right to buy)
|
(1)
|
8/15/2022
|
Common Stock
|
7500
|
$4.71
|
D
|
|
Employee Stock Option (right to buy)
|
(2)
|
7/1/2023
|
Common Stock
|
20000
|
$16.36
|
D
|
|
Employee Stock Option (right to buy)
|
(3)
|
6/4/2024
|
Common Stock
|
25000
|
$13.45
|
D
|
|
Employee Stock Option (right to buy)
|
(4)
|
6/10/2025
|
Common Stock
|
30000
|
$25.41
|
D
|
|
Employee Stock Option (right to buy)
|
(5)
|
6/8/2026
|
Common Stock
|
22000
|
$4.72
|
D
|
|
Explanation of Responses:
|
(1)
|
The option became exercisable as to 25% of the shares on 8/15/2013 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
|
(2)
|
The option became exercisable as to 25% of the shares on 7/1/2014 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
|
(3)
|
The option became exercisable as to 25% of the shares on 6/4/2015 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
|
(4)
|
The option became exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
|
(5)
|
The option became exercisable as to 25% of the shares on 6/8/2017 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Cavanaugh Sarah
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ 08827
|
|
|
SVP of Corp. Affairs & Admin.
|
|
Signatures
|
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
|
|
6/16/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Sep 2023 to Sep 2024